http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1366769-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e0daec85fdd4a4c04e22225e70a5cd9 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7055 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate | 1990-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7aa667e580cbf55114299afa4e6892d2 |
| publicationDate | 2003-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1366769-A1 |
| titleOfInvention | Inhibition of lymphocyte adherence to vascular endothelium utilizing extracellular matrix receptor-ligand interaction |
| abstract | The present invention relates to a method for inhibiting the adhesion of one cell to anotherncomprising interfering with the interaction between the extracellular matrix receptor and itsnligand. The invention is based upon the discovery that the α4β1 extracellular matrix receptornpromotes adhesion of lymphocytes to endothelial cells via attachment to a defined peptidensequence. Prior to the present invention, the ligand of the α4β1 receptor had not beennidentified, nor had the function of the α4β1 receptor in lymphocyte attachment been known.nBy preventing the interaction between the α4β1 receptor and its ligands using antibodies orndefined peptide sequences, the present invention enables, for the first time, specificnintervention in the migration of lymphocytes through the vascular endothelium and intontissues. The present invention, therefore, has particular clinical utility in suppression of thenimmune response, in various specific embodiments of the invention, the adherence ofnlymphocytes to endothelium may be inhibited systemically, or may, alternatively, be localizednto particular tissues or circumscribed areas. Accordingly, the present invention provides forntreatment of diseases involving autoimmune responses as well as other chronic or relapsingnactivations of the immune system, including allergy, asthma, and chronic inflammatory skinnconditions. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7125650-B2 |
| priorityDate | 1989-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.